在帕金森病患者中,宁-血管新生素系统自身抗体网络
Carmen M Labandeira1, Laura Camacho-Meño2, Paula Aracil-Pastor2
1Neurology Service, University Hospital of Ourense, 32005 Ourense, Spain.
Antioxidants (Basel, Switzerland)
|June 26, 2025
概括
这项研究揭示了在帕金森病 (PD) 中准宁-血管素系统 (RAS) 的独特自身抗体网络. 这些发现突出了新的潜在生物标志物和治疗点,通过将PD中的免疫和氧化途径联系起来.
科学领域:
- 神经免疫学 神经免疫学
- 心血管生物学 心血管生物学
- 代谢途径 代谢途径
背景情况:
- 组织-血管素系统 (RAS) 通过相反的轴调节平衡.
- RAS的失调有助于像帕金森病 (PD) 这样的疾病.
- 在PD中观察到对AT1和ACE2的自抗体升高,但其他RAS成分尚未研究.
研究的目的:
- 在PD中调查针对AT2和MasR的自身抗体.
- 探索各种RAS自身抗体 (RAS-AAs) 之间的相关性.
- 在PD中检查RAS-AAs,细胞因子和27-胆固醇之间的联系.
主要方法:
- 使用了与酶相关的免疫吸收试验 (ELISA).
- 分析了来自106名对照组和117名PD患者的血清样本.
- 评估了RAS-AAs,细胞因子和27-胆固醇之间的相关性.
主要成果:
- 患有PD的患者显示MasR-AAs的增加.
- 在PD中观察到RAS-AA (AT1-AA,AT2-AA,MasR-AA,ACE2-AA) 之间的更相互关联的相关性网络.
- 根据性别和年龄,RAS-AA网络有所不同,并且与PD相关的细胞因子和27-胆固醇有关.
- 在调整后,AT1-AAs仍然与PD有显著的关联.
结论:
- 在PD中存在一种特定于疾病的RAS自身抗体网络.
- 这个网络连接了免疫和氧化途径.
- 确定了新的生物标志物模式和PD的潜在治疗点.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
01:37Neural Regulation
40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
01:29Hypertension II: Pathophysiology
90
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
90
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
911
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
911
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
949
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
949
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524